145 related articles for article (PubMed ID: 9113005)
1. End of the line for "third-generation-pill" controversy?
Vandenbroucke JP; Rosendaal FR
Lancet; 1997 Apr; 349(9059):1113-4. PubMed ID: 9113005
[TBL] [Abstract][Full Text] [Related]
2. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral contraceptives on hemostasis and thrombosis.
Rosing J; Tans G
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
[TBL] [Abstract][Full Text] [Related]
5. Factor V Leiden: should we screen oral contraceptive users and pregnant women?
Vandenbroucke JP; van der Meer FJ; Helmerhorst FM; Rosendaal FR
BMJ; 1996 Nov; 313(7065):1127-30. PubMed ID: 8916702
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptive use before and after the latest pill scare in The Netherlands. Changes in oral contraceptive use and how users change.
de Vries CS; van den Berg PB; de Jong-van den Berg LT
Contraception; 1998 Apr; 57(4):247-9. PubMed ID: 9649916
[TBL] [Abstract][Full Text] [Related]
7. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.
Vandenbroucke JP; Helmerhorst FM; Bloemenkamp KW; Rosendaal FR
Am J Obstet Gynecol; 1997 Oct; 177(4):887-91. PubMed ID: 9369840
[TBL] [Abstract][Full Text] [Related]
8. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM
N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445
[TBL] [Abstract][Full Text] [Related]
9. Oral contraception and factor V Leiden mutation in relation to localization of deep vein thrombosis.
Andersen BS; Olsen J
Thromb Res; 1998 May; 90(4):191-4. PubMed ID: 9692618
[TBL] [Abstract][Full Text] [Related]
10. The 1995 pill scare revisited: anatomy of a non-epidemic.
Spitzer WO
Hum Reprod; 1997 Nov; 12(11):2347-57. PubMed ID: 9436662
[TBL] [Abstract][Full Text] [Related]
11. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
12. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
Bennet L; Odeberg H
J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
[TBL] [Abstract][Full Text] [Related]
13. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
14. Third-generation oral contraceptives: how risky?
Weiss N
Lancet; 1995 Dec; 346(8990):1570. PubMed ID: 7500743
[TBL] [Abstract][Full Text] [Related]
15. Resistance to activated protein C in healthy women taking oral contraceptives.
Olivieri O; Friso S; Manzato F; Guella A; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C
Br J Haematol; 1995 Oct; 91(2):465-70. PubMed ID: 8547095
[TBL] [Abstract][Full Text] [Related]
16. Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins.
Olivieri O; Friso S; Manzato F; Grazioli S; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C; Corrocher R
Contraception; 1996 Sep; 54(3):149-52. PubMed ID: 8899255
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives and thrombotic disease: risk of venous thromboembolism.
Helmerhorst FM; Bloemenkamp KW; Rosendaal FR; Vandenbroucke JP
Thromb Haemost; 1997 Jul; 78(1):327-33. PubMed ID: 9198174
[TBL] [Abstract][Full Text] [Related]
18. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
[TBL] [Abstract][Full Text] [Related]
19. Coagulation studies in women using combination type of oral contraceptives.
Sharma S; Sharma M; Soni IJ; Gupta A; Jain R
J Obstet Gynaecol India; 1983 Aug; 33(4):519-24. PubMed ID: 12339832
[TBL] [Abstract][Full Text] [Related]
20. Oral contraceptives, venous thrombosis, and varicose veins. Royal College of General Practitioners' Oral Contraception Study.
J R Coll Gen Pract; 1978 Jul; 28(192):393-9. PubMed ID: 702453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
